Leadership Team

Transverse Medical is led by a team with decades of extensive multi-disciplinary experience in their respective areas of mastery, coupled with expertise in the healthcare industries of structural heart, cardiovascular, and stroke prevention, creating shareholder value, leading and growing medical technology companies, advancing innovative medical device solutions and game changing technologies, and improving patient outcomes.

Eric Goslau

  • Co-Founder, Co-Inventor, Board Director

    Mr. Goslau is an experienced executive with over 25 years of leadership, commercial sales & marketing, product & business development, and entrepreneurship in the medical device industry. Mr. Goslau leads by example with a hands-on approach working side-by-side with his team, key opinion leaders, and clinical operators, providing a balanced team dynamic and unique culture.

    Mr. Goslau is a Co-Founder of Transverse Medical as well as a Co-Inventor on the POINT-GUARD™ Cerebral Embolic Protection Device and serves as a Member of the Board of Directors. As CEO, he leads and oversees all fundraising, operations, clinical planning, regulatory strategy, and product development for the POINT-GUARD™ medical device.

    Mr. Goslau has held previous roles in management and at the director level with small to mid-size, and Fortune 500 commercial stage organizations. His career has provided him end-to-end experience in medical device start-up and early-stage corporate strategy and board room governance, planning and executing at all phases of product development and business functions across highly innovative technologies and multiple procedure applications in Structural Heart, Cardiovascular, Stroke, Peripheral, and Endovascular.

    Throughout his career, Mr. Goslau has introduced a broad offering of life saving technologies ranging from surgical devices, implantable stents, excimer lasers, electrosurgical devices, and complex vascular grafts as well as co-inventing and developing an innovative medical device solution to prevent strokes during cardiovascular procedures. Atop achieving high performing results and outcomes, Mr. Goslau believes in representing and delivering the best quality products to all customers and their patients.

    Mr. Goslau received his Bachelor of Science in business administration with a degree in marketing from the University of Colorado, Leeds School of Business, in Boulder Colorado. Additionally, Mr. Goslau earned a professional executive certificate from UCLA Anderson Graduate School of Business in Strategic Medical Device Marketing.

Ian T. Meredith, MD

  • Professor Ian T. Meredith is currently a Vice Chancellor’s Professorial Fellow at Monash University and a Non-executive director serving on the boards of both private and public companies. He recently retired as the Executive Vice President and Global Chief Medical Officer at Boston Scientific in, Massachusetts USA - a fortune 200, global medical device and technology company of more than 40,000 employees that provides more than 17,000 advanced medical devices and technology solutions to treat over 33 million people in 130 countries every year.

    At BSC, he led clinical innovation, pre-clinical science and medical affairs across the global organization and provided leadership of the company’s clinical trial and R&D strategy. He focused on driving a vision of transformative clinical science and innovative care for all patients with chronic non-communicable diseases through critical clinical input into the company’s new business development plan, M&A strategy, and Venture portfolio.

    Prior to joining Boston Scientific in 2017, Ian was Professor & Director of Monash Heart, the internationally recognized cardiology service within Monash Health, a position he held for 12 years.

    For over 25 years as an Australian practicing clinician, clinical trialist and interventional cardiologist. Ian mentored and fostered the career of a generation of academic and clinical cardiologists, and personally performed more than 20,000 invasive cardiac and coronary procedures. He championed new treatment paradigms into daily clinical practice and was the chief investigator or a principal investigator on more than 30 major international, multi-Centre, randomized trials including many world-first-in-human studies.

    He has published more than 400 peer-reviewed scientific manuscripts, delivered more than 500 invited lectures internationally and nationally and presented as the first operator on numerous live-case operation broadcasts from Monash Heart to most of the leading international clinical conferences globally.

    Ian served as a board member and medical vice-president on both the Heart Foundation of Australia’s National and Victorian state boards and as a national board member of the Cardiac Society of Australia and New Zealand from 2008 until 2016. Ian was the chief medical advocate and face of the Heart Foundation’s national public education campaign on the “Warning signs of a heart attack.” He has also served on numerous professional, state and federal government committees and advisory boards, including the Department of Human Services Cardiac Services Review and the Federal Government Department of Health & Aging Cardiac Prostheses Advisory Group.

    Most notably for Monash University, Ian conceived of, and developed the concept for, the Victorian Heart Hospital in 2005. He spent the subsequent 12 years as the principal driving force and chief medical advocate for the concept as well as the design and planning of the VHH project, Australia’s first purpose built, dedicated, stand-alone, technologically advanced heart hospital.

    Alongside his recent role as EVP and Global CMO for Boston Scientific, Ian served the Victorian State Government as MedTech business ambassador to North America.

    In 2012 Ian received an Order of Australia (AM) in the General Division for outstanding service to medicine in the field of Cardiology as a clinician and researcher and for advisory roles with a range of public health and organizations. In 2019 he received a Doctor of Laws, Honoris Causa for outstanding service to Monash University.

Carl St. Bernard

  • Mr. St. Bernard is currently the President & Chief Executive Officer of Alta Biomaterials. Alta Biomaterials is a private equity funded, start-up medical device company focused on developing and commercializing unique polymer technologies designed to address unmet clinical needs in interventional cardiology, interventional oncology, and other emerging medical applications. Prior to joining Alta Biomaterials, Mr. St. Bernard was President & Chief Executive Officer of Tryton Medical, a start-up interventional medicine company that was successfully exited in 2019.

    Mr. St. Bernard is an independent member of the Board of Directors for Transverse Medical, Inc. Mr. St. Bernard joined the company in March of 2021 and has served as an Executive Advisor and Board Director. Mr. St. Bernard serves on various company committees and provides executive support, leadership, and board governance.

    Mr. St. Bernard has over 30 years of experience in the life sciences field, including pharmaceutical, consumer, medical device, and diagnostics markets. Mr. St. Bernard has broad leadership experience in Cardiology, Ophthalmology, Vascular Surgery, Orthopedics, Radiology, General Surgery, and Plastic Surgery and has held senior executive positions at healthcare leaders such as Johnson & Johnson, Abbott Labs, and GE Healthcare.

    Mr. St. Bernard earned a bachelor’s degree in economics and Studio Art from Lafayette College and a master’s degree in business administration from Pepperdine University.

David Blowers

  • Mr. Blowers is Vice Chairman of Northern Trust, a leading provider of wealth management, asset servicing, asset management and banking services for corporations, institutions, families and individuals. Mr. Blowers joined Northern Trust in September of 1982 and has broad leadership experience in both the institutional and private wealth sides of the business.

    Mr. Blowers is a member of the Board of Directors and serves as Corporate Secretary for Transverse Medical, Inc. Mr. Blowers joined the Board of Directors in August of 2023 following the closing of the company’s Series B1 financing and brings to the board valuable financial experience, board governance, and fiduciary responsibilities.

    Mr. Blowers has enjoyed a successful and privileged career with over 40 years working with Northern Trust and working with both affluent families and large corporations to develop strategies leading towards financial goals. Mr. Blowers has a successful track record of leadership experience in the financial services industry with current responsibilities as one of two Vice Chairmen at the firm where he is focused on senior client relationships, new business development, culture and collaboration, and community engagement.

    Mr. Blowers earned a Bachelor of Arts degree in Government from Lawrence University and an MBA with a concentration in Finance from the Kellogg School at Northwestern University.

Michael Rearden, MD

  • Dr. Michael J. Reardon is a native Houstonian who attended Baylor College of Medicine where he graduated with honors and as a member of AOA. He did his general surgery residency under Dr. Michael DeBakey and cardiothoracic residency under Dr. Denton Cooley. He joined the staff of the Houston Methodist Hospital in 1985 and ran a private practice until 1993. He then joined the full-time faculty of BCM rising to Professor of Surgery with tenure, Chief of Cardiothoracic Surgery and Director of the thoracic residency program. He subsequently joined the academic group at the HMH as Professor of Cardiothoracic Surgery and Chief of Cardiac Surgery.

    Dr. Reardon joined Transverse Medical’s Advisory Board in 2014 and transitioned to Chief Medical Officer in 2020 following the company’s first-in-human experience with the first-generation Point-Guard. Dr. Reardon has been involved with the company through pre-clinical and development activities leading up to in-human clinical trials for the next-generation Point-Guard. His contributions to the development of Point-Guard are coupled with his passion for providing a full-brain protection solution for patients during TAVR and other procedures and where stroke is a risk and embolic protection is of critical importance.

    Dr. Reardon has served as elected president of the medical staff for the HMH and received numerous awards including the Overstreet Award and Noon Award. He currently holds the Allison Family Distinguished Chair of Cardiovascular Research and divides his time between building innovative clinical, research and educational programs.

Erin Spiegel, PhD

  • Erin brings over 20 years of experience in the biotech industry in regulatory affairs, clinical affairs, quality management, and product development of both pharmaceuticals and medical devices. She leads Regulatory, Clinical, and Quality initiatives at Transverse Medical, where she is leading clinical trials and collaboratively ensuring compliance with regulatory requirements for innovative embolic protection devices. 

    Dr. Spiegel holds a PhD in Biophysics and Genetics from the University of Colorado Health Sciences Center. Her diverse scientific expertise encompasses complex genetic engineering, vaccine platform design, and the development and execution of preclinical and clinical studies. She has a proven track record in navigating regulatory landscapes, with multiple successful submissions for INDs, BLAs, 510(k)s, and PMAs. 

    Previously, Erin played a pivotal role at PharmaJet, managing clinical and regulatory affairs, securing over $15 million in non-dilutive funding for needle-free injection technology, and fostering strategic partnerships that expanded the company’s global presence and enabling advancements in nucleic acid-based vaccines and therapeutics. 

    In addition to her leadership roles, Dr. Spiegel is an active member of the Regulatory Affairs community and has contributed to numerous scientific publications and presentations. She is passionate about advancing public health through innovative solutions and is dedicated to fostering a culture of collaboration, integrity, and scientific rigor in the biotech field. 

     

Thomas E. Chilcott

  • Transverse Medical is guided by seasoned executive leadership with deep expertise in healthcare, finance, corporate strategy, and organizational growth. The company benefits from the leadership of Thomas E. Chilcott, a senior finance executive and strategic business leader with a distinguished career spanning public and private healthcare, biotechnology, medical technology, and high-growth organizations.

    Mr. Chilcott brings more than three decades of executive experience leading organizations through transformative growth, capital formation, mergers and acquisitions, operational restructuring, and public market transactions. Throughout his career, he has successfully raised over $175 million in equity and debt financing, completed more than ten mergers and acquisitions, and played key roles in taking multiple companies to national public exchanges, including NASDAQ and NYSE listings.

    Prior to joining Transverse Medical, Mr. Chilcott served as Chief Financial Officer and Treasurer of several healthcare and life sciences organizations, including Theralink Technologies, a precision medicine and molecular diagnostics company, where he led the company’s successful NASDAQ uplisting, secured growth capital, managed investor relations, and built the operational infrastructure necessary to support a publicly traded healthcare enterprise. He also served as CFO of Ampio Pharmaceuticals, where he raised more than $45 million to support late-stage clinical development programs and strengthened governance, compliance, and operational scalability.

    His extensive background includes executive leadership roles in biotechnology, diagnostics, pharmaceuticals, healthcare services, and technology companies, as well as consulting engagements for organizations with revenues ranging from emerging startups to enterprises exceeding $700 million annually. He is recognized for building high-performance teams, improving operational efficiency, implementing scalable financial systems, and aligning strategic initiatives with long-term shareholder and stakeholder value creation.

    At Transverse Medical, Mr. Chilcott provides strategic leadership focused on operational excellence, disciplined financial management, growth initiatives, and creating sustainable value for patients, providers, investors, and business partners. His combination of healthcare industry expertise, public company experience, and proven leadership positions Transverse Medical to successfully execute its mission and growth strategy.

    Education & Credentials: Mr. Chilcott holds a Bachelor of Science in Accountancy from Villanova University and is a Certified Public Accountant (CPA). He is also a member of the Colorado Society of Certified Public Accountants.

    Dr. Spiegel holds a PhD in Biophysics and Genetics from the University of Colorado Health Sciences Center. Her diverse scientific expertise encompasses complex genetic engineering, vaccine platform design, and the development and execution of preclinical and clinical studies. She has a proven track record in navigating regulatory landscapes, with multiple successful submissions for INDs, BLAs, 510(k)s, and PMAs. 

    Previously, Erin played a pivotal role at PharmaJet, managing clinical and regulatory affairs, securing over $15 million in non-dilutive funding for needle-free injection technology, and fostering strategic partnerships that expanded the company’s global presence and enabling advancements in nucleic acid-based vaccines and therapeutics. 

    In addition to her leadership roles, Dr. Spiegel is an active member of the Regulatory Affairs community and has contributed to numerous scientific publications and presentations. She is passionate about advancing public health through innovative solutions and is dedicated to fostering a culture of collaboration, integrity, and scientific rigor in the biotech field.